Elina Jerschow, MDDrug allergies are a major impediment to patient care. Desensitization is the process of decreasing a patient's sensitivity to an allergen over time by injecting gradually increasing amounts of the allergen. When this process is targeted toward enabling patients to tolerate medications to which they are allergic, it is called drug desensitization therapy.
The Division of Allergy & Immunology recently recruited Elina Jerschow, MD, to become director of the Montefiore Drug Desensitization Program.
Dr. Jerschow was previously an associate director of Clinical Research at Merck Research Laboratories, evaluating patient reactions during different phases of the drug development trials. Dr. Jerschow completed a research fellowship in Dermatologic Immunology at the University of California, San Francisco as well as an Internal Medicine residency and a fellowship with extensive bench research in Allergy and Immunology at Albert Einstein College of Medicine. She has been the co-principal investigator in a clinical trial at Einstein involving patients with persistent allergic asthma.